1. Home
  2. ACIU vs DBI Comparison

ACIU vs DBI Comparison

Compare ACIU & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AC Immune SA

ACIU

AC Immune SA

N/A

Current Price

$2.76

Market Cap

247.6M

Sector

Health Care

ML Signal

N/A

Logo Designer Brands Inc.

DBI

Designer Brands Inc.

N/A

Current Price

$6.06

Market Cap

292.0M

ML Signal

N/A

Company Overview

Basic Information
Metric
ACIU
DBI
Founded
2003
1991
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Clothing/Shoe/Accessory Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
247.6M
292.0M
IPO Year
2015
2005

Fundamental Metrics

Financial Performance
Metric
ACIU
DBI
Price
$2.76
$6.06
Analyst Decision
Strong Buy
Hold
Analyst Count
4
2
Target Price
★ $8.57
$6.75
AVG Volume (30 Days)
146.7K
★ 698.7K
Earning Date
11-03-2026
09-10-2026
Dividend Yield
N/A
★ 3.31%
EPS Growth
N/A
★ 15.00
EPS
N/A
★ 0.34
Revenue
N/A
★ $2,892,671,000.00
Revenue This Year
$422.39
$0.73
Revenue Next Year
$377.85
$2.01
P/E Ratio
★ N/A
$18.50
Revenue Growth
★ N/A
N/A
52 Week Low
$2.10
$3.11
52 Week High
$4.00
$9.17

Technical Indicators

Market Signals
Indicator
ACIU
DBI
Relative Strength Index (RSI) 49.96 51.18
Support Level $2.58 $5.96
Resistance Level $2.68 $6.11
Average True Range (ATR) 0.14 0.31
MACD -0.02 0.01
Stochastic Oscillator 49.81 29.89

Price Performance

Historical Comparison
ACIU
DBI

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

About DBI Designer Brands Inc.

Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in two reportable segments: the Retail segment and the Brand Portfolio segment. The Retail segment, which derives key revenue, operates the DSW Designer Shoe Warehouse ("DSW") banner through its direct-to-consumer stores and e-commerce sites in the United States ("U.S.") and Canada, and the Shoe Co. and Rubino banners through its direct-to-consumer stores and e-commerce sites in Canada. The Brand Portfolio segment principally earns revenue from the wholesale of its exclusive and licensed brands to retailers, its Retail segment, and international distributors, and the sale of its Vince Camuto, Keds, and Topo brands through direct-to-consumer e-commerce sites.

Share on Social Networks: